FDA Approves Unknown Drug — TEVA PHARMS

Teva Pharmaceutical announced Friday that it received FDA approval for its Abbreviated New Drug Application, referred to as M-10099, aimed at boosting the adrenocorticotropic hormone levels in patients with central adrenal insufficiency. The approval of this generic equivalent is expected to enhance revenue growth in its radioactive drug franchise with minimal competitive overlap.